Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study

References

• So J, Tang W, Leung WK, et al. Cancer risk in 2621 Chinese patients with inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis. 2017;23(11):2061–2068.
   PubMed Web of Science ®Google Scholar
• Wang LH, Yang YJ, Cheng WC, et al. Higher risk for hematological malignancies in inflammatory bowel disease: a nationwide population-based study in Taiwan. Am J Gastroenterol. 2016;111(9):1313–1319.
   PubMed Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan Let al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9(11):945–965.
   PubMed Web of Science ®Google Scholar
• Laine L, Kaltenbach T, Barkun A, et al. SCENIC International Consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148(3):639–651 e28.
   PubMed Web of Science ®Google Scholar
• Gordillo J, Cabre E, Garcia-Planella E, et al. Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA registry. ECCOJC. 2015;9(12):1063–1070.
   Google Scholar
• Bonovas S, Fiorino G, Lytras T, et al. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(9):1179–1192.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tang W, Wang J, et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control. 2014;25(2):237–249.
   PubMed Web of Science ®Google Scholar
• Samadder NJ, Mukherjee B, Huang SC, et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer. 2011;117(8):1640–1648.
   PubMed Web of Science ®Google Scholar
• Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184–2192.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Cagan A, Cai T, et al. Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14(7):973–979.
   PubMed Web of Science ®Google Scholar
• Shah SC, Glass J, Giustino G, et al. Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease. Gut Liver. 2019;13(1):54–61.
   PubMed Web of Science ®Google Scholar
• Wang A, Aragaki AK, Tang JY, et al. Statin use and all-cancer survival: prospective results from the Women’s Health Initiative. Br J Cancer. 2016;115(1):129–135.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Patrono C. Aspirin and cancer. J Am Coll Cardiol. 2016;68(9):967–976.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164(12):836–845.
   PubMed Web of Science ®Google Scholar
• Cheung KS, Chan EW, Wong AYS, et al. Aspirin and risk of gastric cancer after helicobacter pylori eradication: a territory-wide study. J Natl Cancer Inst. 2018;110(7):743–749.
   PubMedGoogle Scholar
• Simon TG, Ma Y, Ludvigsson JF, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 2018;4(12):1683–1690.
   PubMed Web of Science ®Google Scholar
• Barnard ME, Poole EM, Curhan GC, et al. Association of analgesic use with risk of ovarian cancer in the nurses’ health studies. JAMA Oncol. 2018;4(12):1675–1682.
   PubMed Web of Science ®Google Scholar
• Tsoi KKF, Ho JMW, Chan FCH, et al. Long-term use of low-dose aspirin for cancer prevention: a 10-year population cohort study in Hong Kong. Int J Cancer. 2019;145(1):267–273.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Leung WK. Optimization of inflammatory bowel disease cohort studies in Asia. Intest Res. 2015;13(3):208–212.
   PubMed Web of Science ®Google Scholar
• WHO Collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment, 2015. Oslo. 2014. Available from: https://www.whocc.no/atc_ddd_index/
   Google Scholar
• Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116(3):602–609.
   PubMed Web of Science ®Google Scholar
• Reinacher-Schick A, Seidensticker F, Petrasch S, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy. 2000;32(03):245–254.
   PubMedGoogle Scholar
• Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508–519.
   PubMed Web of Science ®Google Scholar
• Huang WK, Chiou MJ, Yu KH, et al. The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. Aliment Pharmacol Ther. 2013;38(4):432–439.
   PubMed Web of Science ®Google Scholar
• Risch HA, Lu L, Streicher SA, et al. Aspirin use and reduced risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(1):68–74.
   PubMed Web of Science ®Google Scholar
• Burr NE, Hull MA, Subramanian V. Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? World J Gastroenterol. 2016;22(13):3679–3686.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med. 2012;156(5):350–359.
   PubMed Web of Science ®Google Scholar
• Gleeson MH, Davis AJ. Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case-control study. Aliment Pharmacol Ther. 2003;17(6):817–825.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol. 2017;11(3):215.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12(12):1107–1113.
   PubMed Web of Science ®Google Scholar
• Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(2):191–198.
   PubMed Web of Science ®Google Scholar
• Bye WA, Ma C, Nguyen TM, et al. Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a Cochrane systematic review and meta-analysis. Am J Gastroenterol. 2018;113(12):1801–1809.
   PubMed Web of Science ®Google Scholar